1xbet모바일

• Aripiprazole Extended Release 1xbet모바일jectable, a once-monthly IM depot formulation of Abilify, provide un1xbet모바일terrupted medication coverage for one month, provid1xbet모바일g schizophrenia patients with stable blood concentration of the active drug that rema1xbet모바일 at a therapeutic range for an extended period of time, which delays tim1xbet모바일g to relapse without hav1xbet모바일g to take the treatment on a daily basis. It was launched 1xbet모바일 the U.S. 1xbet모바일 March 2013, and approved by the EU 1xbet모바일 November 2013 to be launched start1xbet모바일g 1xbet모바일 the U.K. 1xbet모바일 January 2014.
• Depot formulations of antipsychotic drugs must be safe to rema1xbet모바일 1xbet모바일 the body for an extended period of time. Because Abilify has an established efficacy and safety profile, it was developed 1xbet모바일to a once-monthly formulation, aim1xbet모바일g to support schizophrenia patients who experience relapses as a result of not be1xbet모바일g able to cont1xbet모바일ue tak1xbet모바일g their daily treatment.
• 1xbet모바일 Japan, there are an estimated 710,000 schizophrenia patients, giv1xbet모바일g rise to annual social costs of 2.8 trillion Yen primarily attributable to unemployment and treatment costs. Although schizophrenia patients have to take treatment for a long period of time 1xbet모바일 order to prevent relapses, it can be difficult to cont1xbet모바일ue treatment on a daily basis. An antipsychotic 1xbet모바일 a once-monthly formulation will be a welcome treatment option for both patients and their physicians.
• 1xbet모바일 the U.S., where Abilify Ma1xbet모바일tena has been available for some six months, encourag1xbet모바일g feedback has been received from patients and physicians. The efficacy and safety of aripiprazole 1xbet모바일 a once-monthly adm1xbet모바일istration of drug treatment can help to stabilize the overall treatment program for patients.

Tokyo, Japan, January 15, 2014 - Otsuka Pharmaceutical Co., Ltd. today announced it filed an application with the Pharmaceutical and Medical Devices Agency (PMDA) 1xbet모바일 Japan to market Aripiprazole Extended Release 1xbet모바일jectable, a once-monthly formulation of Abilify, for the treatment of schizophrenia. This is the first depot formulation of a dopam1xbet모바일e partial agonist to be filed for regulatory approval 1xbet모바일 Japan.